Mayo Clinic has bet on chronic disease drug developer Novome Biotechnologies, which is initially targeting a disorder known as hyperoxaluria.

US-based chronic disease medicine developer Novome Biotechnologies has received $33m in a series A round backed by medical research and care provider Mayo Clinic. The round was led by DCVC Bio, a biotech-focused fund run by venture capital firm Data Collective, and included Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.